Evidence map›Paper›PMID 23005263›Full record

ArticleBritish journal of pharmacology2013

Effects of ρ-Da1a a peptidic α(1) (A) -adrenoceptor antagonist in human isolated prostatic adenoma and anaesthetized rats.

S Palea, A Maiga, V Guilloteau, M Rekik, M Guérard, C Rouget, P Rischmann, H Botto, P Camparo, P Lluel and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in British journal of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

S PaleaUROsphere, Faculté des Sciences Pharmaceutiques, Toulouse, France. stefano.palea@urosphere.com
A Maiga
V Guilloteau
M Rekik
M Guérard
C Rouget
P Rischmann
H Botto
P Camparo
P Lluel
N Gilles
Pharmacochimie et Pharmacologie pour le Développement · FRHôpital Foch · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRHôpital Rangueil · FRInstitut de Biologie et Technologies · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeρ-Da1a, a 65 amino-acid peptide, has subnanomolar affinity and high selectivity for the human α(1) (A) -adrenoceptor subtype. The purpose of this study was to characterize the pharmacological effects of ρ-Da1a on prostatic function, both in vivo and in vitro. EXPERIMENTAL APPROACH: ρ-Da1a was tested as an antagonist of adrenaline-induced effects on COS cells transfected with the human α(1) (A) -adrenoceptor as well as on human isolated prostatic adenoma obtained from patients suffering from benign prostatic hyperplasia. Moreover, we compared the effects of ρ-Da1a and tamsulosin on phenylephrine (PHE)-induced increases in intra-urethral (IUP) and arterial pressures (AP) in anaesthetized rats, following i.v. or p.o. administration. KEY

resultsOn COS cells expressing human α(1) (A) -adrenoceptors and on human prostatic strips, ρ-Da1a inhibited adrenaline- and noradrenaline-induced effects. In anaesthetized rats, ρ-Da1a and tamsulosin administered i.v. 30 min before PHE significantly antagonized the effects of PHE on IUP. The pK(B) values for tamsulosin and ρ-Da1a for this effect were similar. With regards to AP, ρ-Da1a only reduced the effect of PHE on AP at the lowest dose tested (10 μg·kg(-1) ), whereas tamsulosin significantly reduced PHE effects at doses between 10 and 150 μg·kg(-1) . CONCLUSIONS AND IMPLICATIONS: ρ-Da1a exhibited a relevant effect on IUP and a small effect on AP. In contrast, tamsulosin antagonized the effects of PHE on both IUP and AP. We conclude that ρ-Da1a is more uroselective than tamsulosin. ρ-Da1a is the most selective peptidic antagonist for α(1A) -adenoceptors identified to date and could be a new treatment for various urological diseases.

Indexed as

Adrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-AgonistsAgedAnesthesiaAnimalsBlood PressureChlorocebus aethiopsCOS CellsElapid VenomsEpinephrineHumansMaleMuscle ContractionMuscle, SmoothNorepinephrinePeptidesAdrenergic alpha-1 Receptor AntagonistsAdrenergic alpha-AgonistsAdTx1 peptide, Dendroaspis angusticepElapid VenomsEpinephrineNorepinephrinePeptidesPhenylephrineReceptors, Adrenergic, alpha-1SulfonamidesTamsulosin

Identifiers

PMID23005263
PMCPMC3579283
OpenAlexW2114736958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.